Article Text

Download PDFPDF
Pharmacological interventions
Adjunctive minocycline in schizophrenia: what one well-conducted study can tell us (and what it can’t)

Statistics from Altmetric.com

Footnotes

  • Contributors Both authors had the idea, wrote and approved the submitted commentary.

  • Competing interests CUC has been a consultant and/or advisor to or has received honoraria from Alkermes, Allergan, Bristol-Myers Squibb, Gerson Lehrman Group, IntraCellular Therapies, Janssen/J&J, LB Pharma, Lundbeck, Medavante, Medscape, Neurocrine, Otsuka, Pfizer, ROVI, Sunovion, Takeda and Teva. He has provided expert testimony for Bristol-Myers Squibb, Janssen and Otsuka. He served on a Data Safety Monitoring Board for Lundbeck and Pfizer. He received grant support from Janssen and Takeda. He is a shareholder of LB Pharma.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.